Viewing nowCombinationEmpa Duo Extended-Release Tablets 12.5/1000 mg (Empagliflozin, Metformin Hydrochloride)
Empagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.

MFDS item code 202500686 · Approved 2025.03.25 · Insurance code 657309230
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication assists patients with type 2 diabetes in achieving better blood sugar control when it is combined with dietary management and exercise. It is particularly used carefully in adult diabetes patients with cardiovascular diseases, helping to manage blood sugar levels safely. The drug combines Empagliflozin and Metformin, which improves blood sugar control and contributes to the prevention of diabetic complications. It is important to follow the physician's instructions during the treatment and regularly monitor the condition. This medication is utilized to effectively support diabetes management.
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. The 25/1000 mg and 10/1000 mg extended-release tablets of this drug should be taken once daily, 1 tablet per dose. Patients taking the 12.5/1000 mg or 5/1000 mg extended-release tablets of this drug should take 2 tablets together once daily. For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medications such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current dose of metformin. If the patient tolerates empagliflozin 10 mg well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this drug is coadministered with a sulfonylurea or insulin, dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dosage adjustment may be required based on renal function, assessment of renal function is recommended before treatment with this drug and periodically thereafter. No dose adjustment of this drug is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other symptoms that may increase the risk of lactic acidosis, this drug may be used with dose adjustment of metformin hydrochloride as follows. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.
This drug is used for the treatment of diabetes and helps control blood sugar levels. It should not be administered to patients with impaired kidney function, and kidney function should be regularly assessed. In cases of severe infection, dehydration, heart failure, or liver impairment, this medication should not be used, especially before and after surgery, during which it should be discontinued for a certain period. While taking this medication, a rare complication called lactic acidosis may occur; symptoms such as muscle pain, difficulty breathing, abdominal pain, and weakness should be reported to a doctor immediately. Additionally, there is a risk of hypoglycemia, so careful monitoring of blood sugar changes is necessary when used in combination with insulin or other antidiabetic medications. This medication may increase the risk of genital infections and urinary tract infections; prompt treatment is necessary if related symptoms manifest. It is safer for pregnant women or those who may become pregnant and breastfeeding women to avoid using this drug. Elderly patients should be particularly cautious due to the risks of dehydration and reduced kidney function when using this medication. The tablets should be swallowed whole without breaking or chewing, and while the tablet shell may be excreted, this is a normal occurrence. In case of overdose, serious side effects such as lactic acidosis may appear, so immediate medical attention should be sought. Alcohol consumption should be avoided while taking this medication, and it is advised to consult a doctor about whether to discontinue this medication when undergoing examinations involving iodinated contrast media before and after taking the drug. Finally, this medication may interact with other drugs, so it is essential to inform your doctor or pharmacist about any other medications being taken.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to protect it from air and moisture. It is recommended to keep the storage temperature between 1 to 30 degrees Celsius.
Light blue oval-shaped extended-release film-coated tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.